HIV-Binding Peptides Neutralizing Viral Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection primarily focus on preventing viral proliferation rather than neutralizing the virus at the entry point, with no clinically approved neutralizing peptides or antibody-based treatments available to prevent HIV from binding to CD4+ cells.
Innovation Solution
Development of recombinant peptides that bind specifically to HIV, comprising certain complementarity determining regions, which prevent the virus from binding to CD4+ cells by targeting a specific epitope on the HIV viral capsid protein, potentially administered alone or in combination with other anti-HIV therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to prevent HIV from binding to CD4+ cells, then viral entry is blocked, but no clinically approved neutralizing peptide treatments are available
Solution Approach 1:
The patent replaces complex monoclonal antibodies with shorter peptides (15-50 amino acids) that are less complex to manufacture and regulate. These peptides achieve neutralization through specific epitope binding (e.g., KLIC sequence) without requiring the full antibody structure, making them more suitable for clinical approval while maintaining effectiveness.
Solution Approach 2:
The invention extracts the essential binding function from full monoclonal antibodies by identifying and utilizing only the critical amino acid sequences (CDRs and epitope-binding regions) needed for HIV neutralization. This extraction creates simplified peptide therapeutics that retain neutralization capability while reducing manufacturing complexity.
2Reliability
If anti-retroviral treatments are administered to prevent viral proliferation, then viral replication is inhibited, but the virus can still enter CD4+ cells
Solution Approach 1:
The patent applies preliminary action by blocking HIV entry into CD4+ cells before viral replication can occur. The peptides bind to HIV envelope proteins (gp120/gp41) and prevent the conformational changes needed for membrane fusion, stopping the infection process at its earliest stage rather than addressing replication later.
Solution Approach 2:
The invention introduces peptide intermediaries that bind to both HIV envelope proteins and CD4+ cell surfaces, preventing the direct interaction between virus and cell. These peptides act as mediators that block the entry pathway without affecting viral replication machinery once inside the cell.
3Reliability
If peptides are designed to bind specifically to HIV epitopes, then neutralization is achieved, but the mechanism must prevent conformational changes in gp120
Solution Approach 1:
The patent applies local quality by designing peptides that target specific local regions (epitopes) on the HIV envelope proteins, particularly the KLIC sequence and other conserved regions. By focusing binding activity on specific local sites rather than requiring global structural interactions, the peptides can prevent conformational changes without needing complex three-dimensional structures themselves.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively neutralize HIV by preventing its entry into CD4+ cells, offering a therapeutic option for treating, preventing, or reducing the risk of HIV infection, as demonstrated by their binding affinity and ability to reduce viral load and increase CD4+ lymphocyte count.
Implementation Method 1
peptides that bind to human immunodeficiency virus (HIV)... wherein the peptide binds to an epitope of HIV comprising the amino acid sequence KLIC and prevents binding (fusion) between HIV and CD4+ cells
Data Source
AI summary
Described are novel HIV-binding peptides and methods of using them for treating or preventing HIV infection and/or the development of AIDS.